Thursday, 5 April 2012

Ak-Dilate Ophthalmic


Generic Name: phenylephrine (Ophthalmic route)

fen-il-EF-rin

Commonly used brand name(s)

In the U.S.


  • AK-Dilate

  • Altafrin

  • Eye Cool

  • Mydfrin

  • Neofrin

  • Neo-Synephrine

  • Ocu-Phrin

  • Prefrin Liquifilm

Available Dosage Forms:


  • Solution

Therapeutic Class: Mydriatic-Cycloplegic


Pharmacologic Class: Sympathomimetic


Chemical Class: Alkylarylamine


Uses For AK-Dilate


Ophthalmic phenylephrine in strengths of 2.5 and 10% is used to dilate (enlarge) the pupil. It is used before eye examinations, before and after eye surgery, and to treat certain eye conditions. In the U.S., these preparations are available only with your doctor's prescription.


Before Using AK-Dilate


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Children may be especially sensitive to the effects of phenylephrine. This may increase the chance of side effects during treatment. In addition, the 10% strength is not recommended for use in infants. Also, the 2.5 and 10% strengths are not recommended for use in low birth weight infants.


Geriatric


Repeated use of 2.5 or 10% phenylephrine may increase the chance of problems during treatment with this medicine. In addition, heart and blood vessel problems have occurred more often in elderly patients than in younger adults.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Clorgyline

  • Iproniazid

  • Isocarboxazid

  • Nialamide

  • Phenelzine

  • Procarbazine

  • Rasagiline

  • Selegiline

  • Tranylcypromine

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Amitriptyline

  • Amoxapine

  • Clomipramine

  • Desipramine

  • Dothiepin

  • Doxepin

  • Furazolidone

  • Imipramine

  • Lofepramine

  • Midodrine

  • Nortriptyline

  • Opipramol

  • Pargyline

  • Protriptyline

  • Trimipramine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Guanethidine

  • Propranolol

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Type 2 diabetes mellitus or

  • Heart or blood vessel disease or

  • High blood pressure—The 2.5 and 10% strengths of phenylephrine may make the condition worse

  • Idiopathic orthostatic hypotension (a certain kind of low blood pressure)—Use of this medicine may cause a large increase in blood pressure to occur

Proper Use of phenylephrine

This section provides information on the proper use of a number of products that contain phenylephrine. It may not be specific to AK-Dilate. Please read with care.


Do not use if the solution turns brown or becomes cloudy.


To use:


  • First, wash your hands. Tilt the head back and, pressing your finger gently on the skin just beneath the lower eyelid, pull the lower eyelid away from the eye to make a space. Drop the medicine into this space. Let go of the eyelid and gently close the eyes. Do not blink. Keep the eyes closed and apply pressure to the inner corner of the eye with your finger for 2 or 3 minutes to allow the medicine to be absorbed by the eye.

  • Immediately after using the eye drops, wash your hands to remove any medicine that may be on them.

  • To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). Also, keep the container tightly closed.

For patients using the 2.5 or 10% eye drops:


  • It is very important that you use this medicine only as directed. Do not use more of it and do not use it more often than your doctor ordered. To do so may increase the chance of too much medicine being absorbed into the body and the chance of side effects. This is especially important when this medicine is used in children or in patients with heart disease or high blood pressure, since high doses of this medicine may cause an irregular heartbeat and an increase in blood pressure.

Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For ophthalmic solution (eye drops) dosage form:
    • For eye redness:
      • Adults and children—Use one drop of 0.12% solution every three or four hours as needed.


    • For eye exams:
      • Adults and children—Use one drop of 2.5% solution. Depending on the eye test to be done, it will take from fifteen minutes to one or two hours for the medicine to work before you can have the eye test.


    • For use before eye surgery:
      • Adults and teenagers—Use one drop of 2.5 or 10% solution thirty to sixty minutes before the start of eye surgery.

      • Children—Use one drop of 2.5% solution thirty to sixty minutes before the start of eye surgery.


    • For certain eye conditions:
      • Adults and teenagers—Depending on the eye condition being treated, your doctor may tell you to use one drop of 2.5 or 10% solution in the eye from once a day to three times a day.

      • Children—Depending on the eye condition being treated, your doctor may tell you to use one drop of 2.5% solution in the eye from once a day to three times a day.



Missed Dose


If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


For non-prescription strength eye drops, follow the package directions.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using AK-Dilate


If eye pain or change in vision occurs or if redness or irritation of the eye continues, gets worse, or lasts for more than 72 hours, stop using the medicine and check with your doctor.


For patients using the 2.5 or 10% eye drops:


  • After you apply this medicine to your eyes, your pupils will become unusually large. This will cause your eyes to become more sensitive to light than they are normally. When you go out during the daylight hours, even on cloudy days, wear sunglasses that block ultraviolet (UV) light to protect your eyes from sunlight and other bright lights. Ordinary sunglasses may not protect your eyes. If you have any questions about the kind of sunglasses to wear, check with your doctor. Also, if this effect continues for longer than 12 hours after you have stopped using this medicine, check with your doctor.

AK-Dilate Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor as soon as possible if any of the following side effects occur:


Symptoms of too much medicine being absorbed into the body - Less common with 10% solution; rare with 2.5% or weaker solution
  • Dizziness

  • fast, irregular, or pounding heartbeat

  • increased sweating

  • increase in blood pressure

  • paleness

  • trembling

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common with 2.5 or 10% solution
  • Burning or stinging of eyes

  • headache or browache

  • sensitivity of eyes to light

  • watering of eyes

Less common
  • Eye irritation not present before use of this medicine

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: AK-Dilate Ophthalmic side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More AK-Dilate Ophthalmic resources


  • AK-Dilate Ophthalmic Side Effects (in more detail)
  • AK-Dilate Ophthalmic Use in Pregnancy & Breastfeeding
  • AK-Dilate Ophthalmic Drug Interactions
  • AK-Dilate Ophthalmic Support Group
  • 0 Reviews for AK-Dilate Ophthalmic - Add your own review/rating


Compare AK-Dilate Ophthalmic with other medications


  • Eye Dryness/Redness
  • Eye Redness/Itching
  • Pupillary Dilation

Tuesday, 3 April 2012

Jumexil




Jumexil may be available in the countries listed below.


Ingredient matches for Jumexil



Selegiline

Selegiline is reported as an ingredient of Jumexil in the following countries:


  • Brazil

Selegiline hydrochloride (a derivative of Selegiline) is reported as an ingredient of Jumexil in the following countries:


  • Brazil

International Drug Name Search

Monday, 2 April 2012

Albuterol extended-release tablets




Generic Name: Albuterol sulfate

Dosage Form: extended-release tablets

4 mg and 8 mg1


Rx only



1

(Each extended-release tablet contains 4.8 mg and 9.6 mg Albuterol sulfate equivalent to 4 mg and 8 mg Albuterol, respectively)


Albuterol Description


Albuterol sulfate extended-release tablets contain Albuterol sulfate, the racemic form of Albuterol and a relatively selective beta2-adrenergic bronchodilator, in an extended-release formulation. Albuterol sulfate has the chemical name (±) a1-[(tert-butyl-amino)methyl]-4-hydroxy-m-xylene-a, a´-diol sulfate (2:1) (salt), and the following structural formula:



Albuterol sulfate has a molecular weight of 576.7, and the molecular formula is (C13H21NO3)2•H2SO4. Albuterol sulfate, USP is a white crystalline powder, soluble in water and slightly soluble in ethanol.


The World Health Organization recommended name for Albuterol base is salbutamol.


Each tablet for oral administration contains 4 mg or 8 mg of Albuterol as 4.8 mg or 9.6 mg, respectively, of Albuterol sulfate, USP. In addition each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, titanium dioxide, triacetin and xanthan gum. The 8 mg tablets also contain the following coloring agents: FD&C Blue #2 aluminum lake and FD&C Yellow #6 aluminum lake.



Albuterol - Clinical Pharmacology


In vitro studies and in vivo pharmacologic studies have demonstrated that Albuterol has a preferential effect on beta2-adrenergic receptors compared with isoproterenol. While it is recognized that beta2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicates that there is a population of beta2-receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established. (See WARNINGS.)


The pharmacologic effects of beta-adrenergic agonist drugs, including Albuterol, are at least in part attributable to stimulation through beta-adrenergic receptors on intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3´, 5´-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.


Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects.


Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-O-methyl transferase.



Preclinical


Intravenous studies in rats with Albuterol sulfate have demonstrated that Albuterol crosses the blood-brain barrier and reaches brain concentrations amounting to approximately 5% of the plasma concentrations. In structures outside the blood-brain barrier (pineal and pituitary glands), Albuterol concentrations were found to be 100 times those in the whole brain.


Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines were administered concurrently. The clinical significance of these findings is unknown.



Pharmacokinetics and Disposition


In a single-dose study comparing one 8 mg Albuterol sulfate extended-release tablet with two 4 mg immediate release Albuterol tablets, USP in 17 normal adult volunteers, the extent of availability of Albuterol sulfate extended-release tablets was shown to be about 80% of Albuterol tablets, USP with or without food. In addition, lower mean peak plasma concentration and longer time to reach the peak level were observed with Albuterol sulfate extended-release tablets as compared with Albuterol tablets, USP. The single-dose study results also showed that food decreases the rate of absorption of Albuterol from Albuterol sulfate extended-release tablets without altering the extent of bioavailability. In addition, the study indicated that food causes a more gradual increase in the fraction of the available dose absorbed from the extended-release formulation as compared with the fasting condition.


In another single-dose study in adults, 8 mg and 4 mg Albuterol sulfate extended-release tablets were shown to deliver dose proportional plasma concentrations in the fasting state. Definitive studies for the effect of food on 4 mg Albuterol sulfate extended-release tablets have not been conducted. However, since food lowers the rate of absorption of 8 mg Albuterol sulfate extended-release tablets, it is expected that food reduces the rate of absorption of 4 mg Albuterol sulfate extended-release tablets also.


Albuterol sulfate extended-release tablets have been formulated to provide duration of action of up to 12 hours. In an 8 day, multiple-dose, crossover study, 15 normal adult male volunteers were given 8 mg Albuterol sulfate extended-release tablets every 12 hours or 4 mg Albuterol tablets, USP every 6 hours. Each dose of Albuterol sulfate extended-release tablets and the corresponding doses of Albuterol tablets, USP were administered in the postprandial state. Steady-state plasma concentrations were reached within 2 days for both formulations. Fluctuations (Cmax−Cmin/Caverage) in plasma concentrations were similar for Albuterol sulfate extended-release tablets administered at 12 hour intervals and Albuterol tablets, USP administered every 6 hours. In addition, the relative bioavailability of Albuterol sulfate extended-release tablets was approximately 100% of the immediate release tablet at steady-state. A summary of these results is shown in the following table:



























Mean Values at Steady-State
CmaxCminTmaxT1/2AUC
(ng/mL)(ng/mL)(h)(h)(ng-h/mL)
Albuterol Sulfate

  Extended-Release

  Tablets
13.78.169.3134
Albuterol

  Tablets, USP
13.98.12.67.2132

The mean plasma Albuterol concentration versus time data at steady-state after the administration of Albuterol sulfate extended-release tablets 8 mg every 12 hours are displayed in the following graph:



Pharmacokinetic studies of 4 mg and 8 mg Albuterol sulfate extended-release tablets have not been conducted in pediatric patients. Bioavailability of 4 mg and 8 mg Albuterol sulfate extended-release tablets in pediatric patients relative to 2 mg and 4 mg immediate release Albuterol has been extrapolated from adult studies showing comparability at steady-state dosing and reduced bioavailability after single-dose administration.



Indications and Usage for Albuterol


Albuterol sulfate extended-release tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.



Contraindications


Albuterol sulfate extended-release tablets are contraindicated in patients with a history of hypersensitivity to Albuterol or any of its components.



Warnings


Immediate hypersensitivity reactions may occur after administration of Albuterol, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema.



Cardiovascular Effects


Albuterol sulfate extended-release tablets, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of Albuterol sulfate extended-release tablets at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, Albuterol sulfate extended-release tablets, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.



Deterioration of Asthma


Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of Albuterol sulfate extended-release tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment; e.g., corticosteroids.



Use of Anti-Inflammatory Agents


The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents; e.g., corticosteroids.



Paradoxical Bronchospasm


Albuterol sulfate extended-release tablets can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, Albuterol sulfate extended-release tablets should be discontinued immediately and alternative therapy instituted.


Rarely, erythema multiforme and Stevens-Johnson Syndrome have been associated with the administration of oral Albuterol in children.



Precautions



General


Albuterol, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.


In controlled clinical trials in adults, patients treated with Albuterol sulfate extended-release tablets had increases in selected serum chemistry values and decreases in selected hematologic values. Increases in SGPT were more frequent among patients treated with Albuterol sulfate extended-release tablets (12 of 247 patients, 4.9%) than among the theophylline (6 of 188 patients, 3.2%) and placebo (1 of 138 patients, 0.7%) groups. Increases in serum glucose concentration were also more frequent among patients treated with Albuterol sulfate extended-release tablets (23 of 234 patients, 9.8%) than among theophylline (11 of 173 patients, 6.45%) and placebo (3 of 129 patients, 2.3%) groups. Increases in SGOT were also more frequent among patients treated with Albuterol sulfate extended-release tablets (10 of 248 patients, 4%) and theophylline (5 of 193, 2.6%) than among patients treated with placebo.


Decreases in white blood cell counts were more frequent in patients treated with Albuterol sulfate extended-release tablets (10 of 247 patients, 4%) compared with patients receiving theophylline (2 of 185 patients, 1.1%) and patients receiving placebo (1 of 141 patients, 0.7%).


Decreases in hemoglobin and hematocrit were more frequent in patients receiving Albuterol sulfate extended-release tablets (16 of 228 patients, 7%, and 17 of 230 patients, 7.4%, respectively) than in patients receiving theophylline (5 of 171 patients, 2.9%, and 9 of 173 patients, 5.2%, respectively) and patients receiving placebo (5 of 129 patients, 3.9%, and 3 of 132 patients, 2.3%, respectively). The clinical significance of these results is unknown.


Large doses of intravenous Albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. As with other beta-agonists, Albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.



Information for Patients


Albuterol sulfate extended-release tablets must be swallowed whole with the aid of liquids. DO NOT CHEW OR CRUSH THESE TABLETS.


The action of Albuterol sulfate extended-release tablets should last up to 12 hours or longer. Albuterol sulfate extended-release tablets should not be used more frequently than recommended. Do not increase the dose or frequency of Albuterol sulfate extended-release tablets without consulting your physician. If you find that treatment with Albuterol sulfate extended-release tablets becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While you are using Albuterol sulfate extended-release tablets, other inhaled drugs and asthma medications should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, tremor or nervousness. If you are pregnant or nursing, contact your physician about use of Albuterol sulfate extended-release tablets. Effective and safe use of Albuterol sulfate extended-release tablets includes an understanding of the way that it should be administered.



Drug Interactions


The concomitant use of Albuterol sulfate extended-release tablets and other oral sympathomimetic agents is not recommended since such combined use may lead to deleterious cardiovascular effects. This recommendation does not preclude the judicious use of an aerosol bronchodilator of the adrenergic stimulant type in patients receiving Albuterol sulfate extended-release tablets. Such concomitant use, however, should be individualized and not given on a routine basis. If regular coadministration is required, then alternative therapy should be considered.


Monoamine Oxidase Inhibitors or Tricyclic Antidepressants

Albuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of Albuterol on the vascular system may be potentiated.


Beta-Blockers

Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Albuterol sulfate extended-release tablets, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.


Diuretics

The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.


Digoxin

Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of Albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving Albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and Albuterol.



Carcinogenesis, Mutagenesis, Impairment of Fertility


In a 2 year study in Sprague-Dawley rats, Albuterol sulfate caused a significant dose related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 2, 10, and 50 mg/kg, (approximately 1/2, 3, and 15 times, respectively, the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 2/5, 2, and 10 times, respectively, the maximum recommended daily oral dose for children on a mg/m2 basis).


In another study this effect was blocked by the coadministration of propranolol, a nonselective beta-adrenergic antagonist.


In an 18 month study in CD-1 mice, Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg (approximately 65 times the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 50 times the maximum recommended daily oral dose for children on a mg/m2 basis).


In a 22 month study in the Golden hamster, Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of 50 mg/kg, (approximately 7 times the maximum recommended daily oral dose for adults and children on a mg/m2 basis).


Albuterol sulfate was not mutagenic in the Ames test with or without metabolic activation using tester strains S. typhimurium TA 1537, TA 1538, and TA98 or E. coli WP2, WP2uvrA, and WP67. No forward mutation was seen in yeast strain S. cerevisiae S9 nor any mitotic gene conversion in yeast strain S. cerevisiae JD1 with or without metabolic activation. Fluctuation assays in S. typhimurium TA98 and E. coli WP2, both with metabolic activation, were negative.


Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at intraperitoneal doses of up to 200 mg/kg.


Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg, (approximately 15 times the maximum recommended daily oral dose for adults on a mg/m2 basis).



Pregnancy


Teratogenic Effects. Pregnancy Category C

Albuterol sulfate has been shown to be teratogenic in mice. A study in CD-1 mice at subcutaneous (SC) doses of 0.025, 0.25, and 2.5 mg/kg, (approximately 3/1000, 3/100, and 3/10 times the maximum recommended daily oral dose for adults on a mg/m2 basis), showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. The drug did not induce cleft palate formation at the lowest dose, 0.025 mg/kg. Cleft palate also occurred in 22 of 72 (30.5%) fetuses of females treated with 2.5 mg/kg, of isoproterenol (positive control) subcutaneously (approximately 3/10 times the maximum recommended daily oral dose for adults on a mg/m2 basis).


A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7/19 fetuses (37%) when Albuterol sulfate was administered orally at a 50 mg/kg dose, (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m2 basis).


There are no adequate and well controlled studies in pregnant women. Albuterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been rarely reported in the offspring of patients being treated with Albuterol. Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned, and a relationship between Albuterol use and congenital anomalies has not been established.



Labor and Delivery


Because of the potential for beta-agonist interference with uterine contractility, use of Albuterol sulfate extended-release tablets for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risks.


Tocolysis

Albuterol has not been approved for the management of pre-term labor. The benefit:risk ratio when Albuterol is administered for tocolysis has not been established. Serious adverse reactions, including pulmonary edema, have been reported during or following treatment of premature labor with beta2-agonists, including Albuterol.



Nursing Mothers


It is not known whether Albuterol is excreted in human milk. Because of the potential for tumorigenicity shown for Albuterol in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.



Pediatric Use


The safety and effectiveness of Albuterol sulfate extended-release tablets have been established in pediatric patients 6 years of age or older. Use of Albuterol sulfate extended-release tablets in these age groups is supported by evidence from adequate and well controlled studies of Albuterol sulfate extended-release tablets in adults; the likelihood that the disease course, pathophysiology, and the drug's effect in pediatric and adult patients are substantially similar; the established safety and effectiveness of immediate release Albuterol tablets in pediatric patients 6 years of age and older; and clinical trials that support the safety of Albuterol sulfate extended-release tablets in pediatric patients over 6 years of age. The recommended dose of Albuterol sulfate extended-release tablets for the pediatric population is based upon the recommended pediatric dosing of immediate-release Albuterol tablets and pharmacokinetic studies in adults showing comparable bioavailability at steady-state dosing and reduced bioavailability after single-dose administration. Safety and effectiveness in pediatric patients below 6 years of age have not been established.



Adverse Reactions


The adverse reactions to Albuterol are similar in nature to reactions to other sympathomimetic agents.


The most frequent adverse reactions to Albuterol are nervousness, tremor, headache, tachycardia, and palpitations.


Less frequent adverse reactions are muscle cramps, insomnia, nausea, weakness, dizziness, drowsiness, flushing, restlessness, irritability, chest discomfort, and difficulty in micturition.


Rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema have been reported after the use of Albuterol.


In addition, Albuterol, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vomiting, vertigo, central nervous system stimulation, unusual taste, and drying or irritation of the oropharynx.


In controlled clinical trials of adult patients conducted in the United States, the following incidence of adverse events was reported:






























































Albuterol Sulfate Extended-Release TabletsTheophyllineOther Beta-AgonistsPlacebo
Event(n = 330)(n = 197)(n = 20)(n = 178)
Tremor24.2%6.1%35%1.1%
Headache18.8%26.9%35%20.8%
Nervousness8.5%5.1%10%2.8%
Nausea/Vomiting4.2%19.8%5%3.9%
Tachycardia2.7%0.5%5%0%
Muscle Cramps2.7%0.5%5%0.6%
Palpitations2.4%0.5%0%1.1%
Insomnia2.4%6.1%0%1.7%
Dizziness1.5%2%0%5.1%
Somnolence0.3%1%0%0.6%

A trend was observed among patients treated with Albuterol sulfate extended-release tablets toward increasing frequency of muscle cramps with increasing patient age (12 to 20 years, 1.2%; 21 to 30 years, 2.6%; 31 to 40 years, 6.9%; 41 to 50 years, 6.9%), compared with no such events in the placebo group. Also observed was an increasing frequency of tremor with increasing patient age (12 to 20 years, 29.4%; 21 to 30 years, 29.9%; 31 to 40 years, 27.6%; 41 to 50 years, 37.9%), compared to 2.9% or less in the placebo group.


The reactions are generally transient in nature, and it is usually not necessary to discontinue treatment with Albuterol sulfate extended-release tablets.



Overdosage


The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS; e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Hypokalemia may also occur. As with all sympathomimetic aerosol medications, cardiac arrest and even death may be associated with abuse of Albuterol sulfate extended-release tablets.


Treatment consists of discontinuation of Albuterol sulfate extended-release tablets together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Albuterol sulfate extended-release tablets.


The oral median lethal dose of Albuterol sulfate in mice is greater than 2000 mg/kg, (approximately 250 times the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 200 times the maximum recommended daily oral dose for children on a mg/m2 basis). In mature rats, the subcutaneous median lethal dose of Albuterol sulfate is approximately 450 mg/kg (approximately 110 times the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 90 times the maximum recommended daily oral dose for children on a mg/m2 basis). In small young rats, the subcutaneous median lethal dose is approximately 2000 mg/kg, (approximately 500 times the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 400 times the maximum recommended daily oral dose for children on a mg/m2 basis).



Albuterol Dosage and Administration


The following dosages of Albuterol sulfate extended-release tablets are expressed in terms of Albuterol base:



Usual Dosage


Adults and Children Over 12 Years of Age

The usual recommended dosage for adults and pediatric patients over 12 years of age is 8 mg every 12 hours. In some patients, 4 mg every 12 hours may be sufficient.


Children 6 to 12 Years of Age

The usual recommended dosage for children 6 through 12 years of age is 4 mg every 12 hours.


Dosage Adjustment in Adults and Children Over 12 Years of Age

In unusual circumstances, such as adults of low body weight, it may be desirable to use a starting dosage of 4 mg every 12 hours and progress to 8 mg every 12 hours according to response.


If control of reversible airway obstruction is not achieved with the recommended doses in patients on otherwise optimized asthma therapy, the doses may be cautiously increased stepwise under the control of the supervising physician to a maximum dose of 32 mg per day in divided doses (i.e., every 12 hours).


Dosage Adjustment in Children 6 to 12 Years of Age

If control of reversible airway obstruction is not achieved with the recommended doses in patients on otherwise optimized asthma therapy, the doses may be cautiously increased stepwise under the control of the supervising physician to a maximum dose of 24 mg per day in divided doses (i.e., every 12 hours).


Switching From Oral Albuterol, USP Products

Patients currently maintained on Albuterol tablets, USP or Albuterol sulfate syrup can be switched to Albuterol sulfate extended-release tablets. For example, the administration of one 4 mg Albuterol sulfate extended-release tablet every 12 hours is comparable to one 2 mg Albuterol tablet, USP every 6 hours. Multiples of this regimen up to the maximum recommended daily dose also apply.



Albuterol sulfate extended-release tablets must be swallowed whole with the aid of liquids. DO NOT CHEW OR CRUSH THESE TABLETS.



How is Albuterol Supplied


Albuterol Sulfate Extended-release Tablets are available containing 4 mg and 8 mg of Albuterol.


The 4 mg tablets are white film-coated, round, unscored tablets debossed with M on one side of the tablet and 22 on the other side. They are available as follows:


NDC 0378-4122-01

bottles of 100 tablets


NDC 0378-4122-05

bottles of 500 tablets


The 8 mg tablets are blue film-coated, round, unscored tablets debossed with M on one side of the tablet and 24 on the other side. They are available as follows:


NDC 0378-4124-01

bottles of 100 tablets


NDC 0378-4124-05

bottles of 500 tablets


Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]


Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.



Mylan Pharmaceuticals Inc.

Morgantown, WV 26505


REVISED JULY 2006

ALBER:R1








Albuterol SULFATE 
Albuterol sulfate  tablet, film coated, extended release










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0378-4122
Route of AdministrationORALDEA Schedule    






































INGREDIENTS
Name (Active Moiety)TypeStrength
Albuterol Sulfate (Albuterol)Active4 MILLIGRAM  In 1 TABLET
colloidal silicon dioxideInactive 
hypromelloseInactive 
magnesium stearateInactive 
microcrystalline celluloseInactive 
polydextroseInactive 
polyethylene glycolInactive 
sodium lauryl sulfateInactive 
titanium dioxideInactive 
triacetinInactive 
xanthan gumInactive 






















Product Characteristics
ColorWHITEScoreno score
ShapeROUNDSize6mm
FlavorImprint CodeM;22
Contains      
CoatingtrueSymbolfalse














Packaging
#NDCPackage DescriptionMultilevel Packaging
10378-4122-01100 TABLET In 1 BOTTLE, PLASTICNone
20378-4122-05500 TABLET In 1 BOTTLE, PLASTICNone






Albuterol SULFATE 
Albuterol sulfate  tablet, film coated, extended release










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0378-4124
Route of AdministrationORALDEA Schedule    












































INGREDIENTS
Name (Active Moiety)TypeStrength
Albuterol Sulfate (Albuterol)Active8 MILLIGRAM  In 1 TABLET
colloidal silicon dioxideInactive 
hypromelloseInactive 
magnesium stearateInactive 
microcrystalline celluloseInactive 
polydextroseInactive 
polyethylene glycolInactive 
sodium lauryl sulfateInactive 
titanium dioxideInactive 
triacetinInactive 
xanthan gumInactive 
FD&C blue #2 aluminum lakeInactive 
FD&C yellow #6 aluminum lakeInactive 






















Product Characteristics
ColorBLUEScoreno score
ShapeROUNDSize6mm
FlavorImprint CodeM;24
Contains      
CoatingtrueSymbolfalse














Packaging
#NDCPackage DescriptionMultilevel Packaging
10378-4124-01100 TABLET In 1 BOTTLE, PLASTICNone
20378-4124-05500 TABLET In 1 BOTTLE, PLASTICNone

Revised: 05/2007Mylan Pharmaceuticals Inc.

More Albuterol resources


  • Albuterol Side Effects (in more detail)
  • Albuterol Dosage
  • Albuterol Use in Pregnancy & Breastfeeding
  • Drug Images
  • Albuterol Drug Interactions
  • Albuterol Support Group
  • 34 Reviews for Albuterol - Add your own review/rating


Compare Albuterol with other medications


  • Asthma, acute
  • Asthma, Maintenance
  • Bronchospasm Prophylaxis
  • COPD, Acute
  • COPD, Maintenance

Collagenase Santyl




Collagenase Santyl® Ointment

250 units/g

Rx only



DESCRIPTION


Collagenase Santyl® Ointment is a sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme collagenase is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue.



CLINICAL PHARMACOLOGY


Since collagen accounts for 75% of the dry weight of skin tissue, the ability of collagenase to digest collagen in the physiological pH and temperature range makes it particularly effective in the removal of detritus.1 Collagenase thus contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas. 2, 3, 4, 5, 6 Collagen in healthy tissue or in newly formed granulation tissue is not attacked. 2, 3, 4, 5, 6, 7, 8 There is no information available on collagenase absorption through skin or its concentration in body fluids associated with therapeutic and/or toxic effects, degree of binding to plasma proteins, degree of uptake by a particular organ or in the fetus, and passage across the blood brain barrier.



INDICATIONS AND USAGE


Collagenase Santyl® Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21



CONTRAINDICATIONS


Collagenase Santyl® Ointment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase.



PRECAUTIONS


The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. When it is suspected such materials have been used, the site should be carefully cleansed by repeated washings with normal saline before Collagenase Santyl® Ointment is applied. Soaks containing metal ions or acidic solutions should be avoided because of the metal ion and low pH. Cleansing materials such as Dakin's solution and normal saline are compatible with Collagenase Santyl® Ointment.


Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia.


A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when Collagenase Santyl® Ointment was not confined to the wound. Therefore, the ointment should be applied carefully within the area of the wound. Safety and effectiveness in pediatric patients have not been established.



ADVERSE REACTIONS


No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. However, one case of systemic manifestations of hypersensitivity to collagenase in a patient treated for more than one year with a combination of collagenase and cortisone has been reported.



OVERDOSAGE


No systemic or local reaction attributed to overdose has been observed in clinical investigations and clinical use. If deemed necessary the enzyme may be inactivated by washing the area with povidone iodine.



DOSAGE AND ADMINISTRATION


Collagenase Santyl® Ointment should be applied once daily (or more frequently if the dressing becomes soiled, as from incontinence). When clinically indicated, crosshatching thick eschar with a #10 blade allows Collagenase Santyl® Ointment more surface contact with necrotic debris. It is also desirable to remove, with forceps and scissors, as much loosened detritus as can be done readily. Use Collagenase Santyl® Ointment in the following manner:


  1. Prior to application the wound should be cleansed of debris and digested material by gently rubbing with a gauze pad saturated with normal saline solution, or with the desired cleansing agent compatible with Collagenase Santyl® Ointment (See PRECAUTIONS), followed by a normal saline solution rinse.

  2. Whenever infection is present, it is desirable to use an appropriate topical antibiotic powder. The antibiotic should be applied to the wound prior to the application of Collagenase Santyl® Ointment. Should the infection not respond, therapy with Collagenase Santyl® Ointment should be discontinued until remission of the infection.

  3. Collagenase SantyI® Ointment may be applied directly to the wound or to a sterile gauze pad which is then applied to the wound and properly secured.

  4. Use of Collagenase Santyl® Ointment should be terminated when debridement of necrotic tissue is complete and granulation tissue is well established.


HOW SUPPLIED


Collagenase Santyl® Ointment contains 250 units of collagenase enzyme per gram of white petrolatum USP.


Do not store above 25°C (77°F). Sterility guaranteed until tube is opened.


Collagenase Santyl® Ointment is available in 15 gram and 30 gram tubes.



REFERENCES


  1. Mandl, I., Adv Enzymol. 23:163,1961.

  2. Boxer, A.M., Gottesman, N., Bernstein, H., & Mandl, I., Geriatrics. 24:75,1969.

  3. Mazurek, I., Med. Welt. 22:150, 1971.

  4. Zimmerman, WE., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 131, p. 185.

  5. Vetra, H., & Whittaker, D., Geriatrics. 30:53, 1975.

  6. Rao, D.B., Sane, P.G., & Georgiev, E.L., J. Am. Geriatrics Soc. 23:22, 1975.

  7. Vrabec, R., Moserova, J., Konickova, Z., Behounkova, E., & Blaha, J., J. Hyg. Epidemiol. Microbiol. Immunol. 18:496, 1974.

  8. Lippmann, H.I., Arch. Phys. Med. Rehabil. 54:588, 1973.

  9. German, F.M., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 165.

  10. Haimovici, H. & Strauch, B., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 177.

  11. Lee, L.K., & Ambrus, J.L., Geriatrics. 30:91, 1975.

  12. Locke, R.K., & Heifitz, N.M., J. Am. Pod. Assoc. 65:242, 1975.

  13. Varma, A.O., Bugatch, E., & German, F.M., Surg. Gynecol. Obstet. 136:281, 1973.

  14. Barrett D., Jr., & Klibanski, A., Am. J. Nurs. 73:849, 1973.

  15. Bardfeld, L.A., J. Pod. Ed. 1:41, 1970.

  16. Blum, G., Schweiz. Rundschau Med Praxis. 62:820,1973. Abstr. in Dermatology Digest, Feb. 1974, p. 36.

  17. Zaruba, F., Lettl, A., Brozkova, L., Skrdlantova, H., & Krs, V., J. Hyg. Epidemiol. Microbiol. Immunol. 18:499, 1974.

  18. Altman, M.I., Goldstein, L., & Horwitz, S., J. Am. Pod. Assoc. 68:11, 1978.

  19. Rehn, V.J., Med. Klin. 58:799, 1963.

  20. Krauss, H., Koslowski, L., & Zimmermann W.E., Langenbecks Arch. Klin. Chir. 303:23, 1963.

  21. Gruenagel, H.H., Med. Klin. 58:442, 1963.

Marketed by: HEALTHPOINT®


1-800-441-8227

Healthpoint, Ltd.

Fort Worth, Texas 76107


Manufactured for DFB Biotech, Inc.

Fort Worth, Texas 76107

US Gov't License #1745


Distributed by: DPT Laboratories, Ltd.

San Antonio, Texas 78215


Reorder Nos.

0064-5010-15 (15g tube)

0064-5010-30 (30g tube)


© 2009 Healthpoint, Ltd.


SANTYL is a registered trademark of Healthpoint, Ltd.


129128-0809



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL










Collagenase Santyl 
Collagenase Santyl  ointment










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0064-5010
Route of AdministrationTOPICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
COLLAGENASE (COLLAGENASE)COLLAGENASE250 U  in 1 g






Inactive Ingredients
Ingredient NameStrength
PETROLATUM 


















Product Characteristics
ColorWHITE (to off-white)Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
10064-5010-1515 g In 1 TUBENone
20064-5010-3030 g In 1 TUBENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
BLABLA10199510/18/2006


Labeler - HEALTHPOINT, LTD (965634504)
Revised: 01/2011HEALTHPOINT, LTD

More Collagenase Santyl resources


  • Collagenase Santyl Side Effects (in more detail)
  • Collagenase Santyl Use in Pregnancy & Breastfeeding
  • Collagenase Santyl Drug Interactions
  • Collagenase Santyl Support Group
  • 0 Reviews for Collagenase Santyl - Add your own review/rating


Compare Collagenase Santyl with other medications


  • Actinic Keratosis

Sunday, 1 April 2012

NeoClarityn Oral Solution





1. Name Of The Medicinal Product



Neoclarityn 0.5 mg/ml oral solution


2. Qualitative And Quantitative Composition



Each ml of oral solution contains 0.5 mg desloratadine.



This medicinal product contains 150 mg/ml of sorbitol



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Oral solution



4. Clinical Particulars



4.1 Therapeutic Indications



Neoclarityn is indicated for the relief of symptoms associated with:



- allergic rhinitis (see section 5.1)



- urticaria (see section 5.1)



4.2 Posology And Method Of Administration



Neoclarityn may be taken without regard to mealtime for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1).



The prescriber should be aware that most cases of rhinitis below 2 years of age are of infectious origin (see section 4.4) and there are no data supporting the treatment of infectious rhinitis with Neoclarityn.



Children 1 through 5 years of age: 2.5 ml (1.25 mg) Neoclarityn oral solution once a day.



Children 6 through 11 years of age: 5 ml (2.5 mg) Neoclarityn oral solution once a day.



In adults and adolescents (12 years of age and over): 10 ml (5 mg) Neoclarityn oral solution once a day.



There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see sections 4.8 and 5.1).



Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient's disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.



In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.



4.3 Contraindications



Hypersensitivity to the active substance, to any of the excipients, or to loratadine.



4.4 Special Warnings And Precautions For Use



Efficacy and safety of Neoclarityn oral solution in children under 1 year of age have not been established.



In children below 2 years of age, the diagnosis of allergic rhinitis is particularly difficult to distinguish from other forms of rhinitis. The absence of upper respiratory tract infection or structural abnormalities, as well as patient history, physical examinations, and appropriate laboratory and skin tests should be considered.



Approximately 6 % of adults and children 2- to 11-year old are phenotypic poor metabolisers of desloratadine and exhibit a higher exposure (see section 5.2). The safety of desloratadine in children 2- to 11-years of age who are poor metabolisers is the same as in children who are normal metabolisers. The effects of desloratadine in poor metabolisers < 2 years of age have not been studied.



In the case of severe renal insufficiency, Neoclarityn should be used with caution (see section 5.2).



This medicinal product contains sorbitol; thus, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No clinically relevant interactions were observed in clinical trials with Neoclarityn tablets in which erythromycin or ketoconazole were co-administered (see section 5.1).



In a clinical pharmacology trial, Neoclarityn tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1).



4.6 Pregnancy And Lactation



Desloratadine was not teratogenic in animal studies. The safe use of the medicinal product during pregnancy has not been established. The use of Neoclarityn during pregnancy is therefore not recommended.



Desloratadine is excreted into breast milk, therefore the use of Neoclarityn is not recommended in breastfeeding women.



4.7 Effects On Ability To Drive And Use Machines



In clinical trials that assessed the driving ability, no impairment occurred in patients receiving desloratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.



4.8 Undesirable Effects



In clinical trials in a paediatric population, the desloratadine syrup formulation was administered to a total of 246 children aged 6 months through 11 years. The overall incidence of adverse events in children 2 through 11 years of age was similar for the desloratadine and the placebo groups. In infants and toddlers aged 6 to 23 months, the most frequent adverse events reported in excess of placebo were diarrhoea (3.7 %), fever (2.3 %) and insomnia (2.3 %). In an additional study, no adverse events were seen in subjects between 6 and 11 years of age following a single 2.5 mg dose of desloratadine oral solution.



At the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with Neoclarityn were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse events reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %). Other undesirable effects reported very rarely during the post-marketing period are listed in the following table.


















Psychiatric disorders




Hallucinations




Nervous system disorders




Dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures




Cardiac disorders




Tachycardia, palpitations




Gastrointestinal disorders




Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea




Hepatobiliary disorders




Elevations of liver enzymes, increased bilirubin, hepatitis




Musculoskeletal and connective tissue disorders




Myalgia




General disorders




Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria)



4.9 Overdose



In the event of overdose, consider standard measures to remove unabsorbed active substance.



Symptomatic and supportive treatment is recommended.



Based on a multiple dose clinical trial in adults and adolescents, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.



Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: antihistamines – H1 antagonist, ATC code: R06A X27



Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors because the substance is excluded from entry to the central nervous system.



Desloratadine has demonstrated antiallergic properties from in vitro studies. These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.



Efficacy of Neoclarityn oral solution has not been investigated in separate paediatric trials. However, the safety of Neoclarityn syrup, which contains the same concentration of desloratadine, was demonstrated in three paediatric trials. Children, 1-11 years of age, who were candidates for antihistamine therapy received a daily desloratadine dose of 1.25 mg (1 through 5 years of age) or 2.5 mg (6 through 11 years of age). Treatment was well tolerated as documented by clinical laboratory tests, vital signs, and ECG interval data, including QTc. When given at the recommended doses, the plasma concentrations of desloratadine (see section 5.2) were comparable in the paediatric and adult populations. Thus, since the course of allergic rhinitis/chronic idiopathic urticaria and the profile of desloratadine are similar in adults and paediatric patients, desloratadine efficacy data in adults can be extrapolated to the paediatric population.



In a multiple dose clinical trial, in adults and adolescents, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in adults and adolescents, in which desloratadine was administered to adults at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.



Desloratadine does not readily penetrate the central nervous system. In controlled clinical trials, at the recommended dose of 5 mg daily for adults and adolescents, there was no excess incidence of somnolence as compared to placebo. Neoclarityn tablets given at a single daily dose of 7.5 mg to adults and adolescents did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.



In clinical pharmacology trials in adults, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol.



No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose ketoconazole and erythromycin interaction trials.



Efficacy of Neoclarityn syrup has not been investigated in paediatric trials in children less than 12 years of age.



In adult and adolescent patients with allergic rhinitis, Neoclarityn tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. Neoclarityn effectively controlled symptoms for 24 hours. The efficacy of Neoclarityn tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.



In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of symptoms. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.



Neoclarityn tablets were effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms.



Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.



In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Neoclarityn was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Neoclarityn also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.



5.2 Pharmacokinetic Properties



Desloratadine plasma concentrations can be detected within 30 minutes of desloratadine administration in adults and adolescents. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg.



In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metaboliser phenotype was comparable for adult (6 %) and paediatric subjects 2- to 11-year old (6 %), and greater among Blacks (18 % adult, 16 % paediatric) than Caucasians (2 % adult, 3 % paediatric) in both populations.



In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.



Similar pharmacokinetic parameters were observed in a multiple-dose pharmacokinetic study conducted with the syrup formulation in paediatric poor metaboliser subjects 2- to 11-year old diagnosed with allergic rhinitis. The exposure (AUC) to desloratadine was about 6-fold higher and the Cmax was about 3 to 4 fold higher at 3-6 hours with a terminal half-life of approximately 120 hours. Exposure was the same in adult and paediatric poor metabolisers when treated with age-appropriate doses. The overall safety profile of these subjects was not different from that of the general population. The effects of desloratadine in poor metabolizers < 2 years of age have not been studied.



Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant active substance accumulation following once daily adult and adolescent dosing of desloratadine (5 mg to 20 mg) for 14 days.



In a single dose, crossover study of desloratadine, the tablet and the syrup formulations were found to be bioequivalent. As Neoclarityn oral solution contains the same concentration of desloratadine, no bioequivalence study was required and it is expected to be equivalent to the syrup and tablet.



In separate single dose studies, at the recommended doses, paediatric patients had comparable AUC and Cmax values of desloratadine to those in adults who received a 5 mg dose of desloratadine syrup.



The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products can not be fully excluded. Desloratadine does not inhibit CYP3A4 in vivo, and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.



In a single dose trial using a 7.5 mg dose of desloratadine, there was no effect of food (high-fat, high caloric breakfast) on the disposition of desloratadine. In another study, grapefruit juice had no effect on the disposition of desloratadine.



5.3 Preclinical Safety Data



Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.



Non-clinical data with desloratadine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.



6. Pharmaceutical Particulars



6.1 List Of Excipients



sorbitol,



propylene glycol,



sucralose E 955,



hypromellose 2910,



sodium citrate dihydrate,



natural and artificial flavour (bubblegum),



citric acid anhydrous,



disodium edetate,



purified water



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



2 years



6.4 Special Precautions For Storage



Do not freeze. Store in the original package.



6.5 Nature And Contents Of Container



Neoclarityn oral solution, is supplied in 30, 50, 60, 100, 120, 150, 225 and 300 ml size Type III amber glass bottles closed with a plastic child resistant (C/R) screw closure having a multi-ply polyethylene-faced liner. All packages except the 150 ml package are supplied with a measuring spoon marked for doses of 2.5 ml and 5 ml. For the 150 ml package, a measuring spoon or an oral measuring syringe is provided, marked for doses of 2.5 ml and 5 ml.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



7. Marketing Authorisation Holder



Merck Sharp & Dohme Ltd



Hertford Road



Hoddesdon



Hertfordshire



EN11 9BU



United Kingdom



8. Marketing Authorisation Number(S)



EU/1/00/161/059-067



9. Date Of First Authorisation/Renewal Of The Authorisation



Date of first authorisation: 15 January 2001



Date of last renewal: 15 January 2006



10. Date Of Revision Of The Text



16 September 2011



Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/



11. LEGAL CATEGORY


Prescription Only Medicine



NeoClarityn Oral Sol/SPC/EU/09-11/04